Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label CDP870 monotherapy in rheumatoid arthritis (Japan)
jRCT2080220676Phase 3
- Sponsor
- Astellas Pharma
- Start
- Feb 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of certolizumab pegol in rheumatoid arthritis (RA) (2 arms), sponsored by Astellas Pharma.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080220676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220676.